Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinflunine plus methotrexate versus methotrexate in recurrent/metastatic head and neck squamous cell carcinoma after platinum
2011-005081-38Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Vinflunine (JAVLOR) + methotrexate with Methotrexate alone (2 arms). Primary endpoint: overall survival. Started Mar 2012; status: completed.
02
Drugs
vinfluninemethotrexate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-005081-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005081-38.